GSA Capital Partners LLP Decreases Stock Holdings in Boston Scientific Corporation $BSX

GSA Capital Partners LLP decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 46.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,232 shares of the medical equipment provider’s stock after selling 8,803 shares during the period. GSA Capital Partners LLP’s holdings in Boston Scientific were worth $976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BSX. Murphy & Mullick Capital Management Corp lifted its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $26,000. United Community Bank lifted its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares in the last quarter. Colonial Trust Co SC lifted its position in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares in the last quarter. Finally, Bangor Savings Bank lifted its position in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Insider purchases are often viewed as a sign of management confidence in the company’s outlook and can support sentiment around the stock.
• Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. The FRACTURE trial met all primary safety and effectiveness endpoints, which strengthens the case for a future regulatory submission and supports the company’s growth story in interventional cardiology.
• Neutral Sentiment: Baird kept an Outperform rating on Boston Scientific, though it trimmed its price target to $75 from $78. That suggests the firm still sees upside, but the lower target may temper enthusiasm somewhat.
• Negative Sentiment: Recent commentary also pointed to Boston Scientific having fallen on weak results, and the stock remains well below its longer-term moving averages. That indicates investors are still weighing execution concerns and broader pressure on the shares despite the upbeat insider and clinical developments.

Boston Scientific Stock Up 0.7%

NYSE BSX opened at $57.08 on Friday. Boston Scientific Corporation has a 52 week low of $52.52 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The business’s fifty day simple moving average is $62.21 and its 200-day simple moving average is $80.40. The firm has a market cap of $84.84 billion, a PE ratio of 23.88, a P/E/G ratio of 1.04 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 EPS. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BSX. Needham & Company LLC reiterated a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a research report on Monday. Bank of America decreased their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday. Truist Financial decreased their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, April 23rd. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, Robert W. Baird decreased their price objective on Boston Scientific from $78.00 to $75.00 and set an “outperform” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $92.71.

Insider Buying and Selling

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.